Credit Suisse Ag 2seventy Bio, Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$3.14 - $11.2 $698,637 - $2.49 Million	222,496 Added 21.79%	1,243,449 $4.87 Million
Q2 2023 Aug 11, 2023	BUY	$8.45 - $12.48 $25,172 - $37,177	2,979 Added 0.29%	1,020,953 $10.3 Million
Q1 2023 May 10, 2023	BUY	$9.21 - $14.98 $103,437 - $168,240	11,231 Added 1.12%	1,017,974 $10.4 Million
Q4 2022 Feb 13, 2023	BUY	$8.57 - $17.0 $8,510 - $16,881	993 Added 0.1%	1,006,743 $9.43 Million
Q3 2022 Nov 10, 2022	SELL	$12.56 - $17.54 $7,686 - $10,734	-612 Reduced 0.06%	1,005,750 $14.6 Million
Q2 2022 Aug 12, 2022	BUY	$10.55 - $18.81 $20,994 - $37,431	1,990 Added 0.2%	1,006,362 $13.3 Million
Q1 2022 May 16, 2022	BUY	$11.67 - $26.72 $1.99 Million - $4.57 Million	170,888 Added 20.5%	1,004,372 $17.1 Million
Q4 2021 Feb 14, 2022	BUY	$13.77 - $42.56 $11.5 Million - $35.5 Million	833,484 New	833,484 $21.4 Million

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $137M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.